|
AD Connect
User
Home
Discussions
Datasets
Tech Help
Events
Video Library
FDSA
Datasets
Datasets
Datasets
Forums
Tags
More
Cancel
New
Dataset Categories Navigation
-
Datasets
-
Region
+
Clinical Trial
+
Data Type
+
Disease
Africa
Asia
Europe
Middle East
North America
Oceania
South America
Datasets
Datasets
Region
Datasets
A Single Blind, Placebo-controlled, Randomised Study in Mild to Moderate Alzheimer's Disease Patients to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK239512, a Selective...
This is a safety and tolerability study to investigate the effect of GSK239512 on mild to moderate Alzheimer's disease patients. The dose of GSK239512 will be titrated to reach the most well tolerated…
A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of the H3 Receptor Antagonist, GSK239512 in Subjects With Mild to Moderate Alzheimer's Disease
What is it and what does it include? This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with mild to moderate Alzheimer's. This…
A Study of Semagacestat for Alzheimer's Patients
The primary objective of the original study was to assess the safety of semagacestat in Alzheimer's disease (AD) patients during 24 months of open-label treatment. Baseline for the efficacy measures is…
